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Abstract: The article tries to reply to the following three 
questions: Are External Quality Assessment Schemes 
(EQAS) really fit for purpose? Are all schemes equivalent 
and sufficiently harmonized? Is the role of EQAS similar and 
necessary in all branches of laboratory medicine? Although 
the reply to the first two questions is, unfortunately, nega-
tive for several reasons (lack of commutable material with 
reference method values, EQAS with different scopes, 
etc.), the reply to the third one is positive: EQAS are a nec-
essary source of information on trueness and accuracy 
and must be fully developed for all the branches of the 
clinical laboratory.
Keywords: accreditation; accuracy; External Quality 
Assessment Schemes.
Introduction
External Quality Assessment Schemes (EQAS) play a 
central role in laboratory medicine [1]. In Europe, success-
ful participation in EQA programs is set as a mandatory 
requisite by country-specific accreditation bodies such as 
the Italian Accreditation Body (Accredia) and the Board 
of Accreditation (RvA) in the Netherlands, to have access 
to the ISO 15189 accreditation according to the flexible 
scope approach [2]. ISO 15189:2012 dedicates a full para-
graph 5.6.3 to interlaboratory comparisons [3]. EQAS are 
(or should be) the final step to confirm the success of 
the traceability chain [4] and are also seen as part of the 
surveillance of the performances of the In Vitro Diagnostic 
medical tests [5]. Thus, although there is no doubt about 
their importance, the questions are as follows: Are EQAS 
really fit for purpose? Are all EQAS equivalent and suffi-
ciently harmonized? Is their role similar and necessary in 
all branches of laboratory medicine?
Present situation
Miller already in 2009 clearly indicated advantages and 
limitations of participation in an EQAS [6] and 2  years 
later, together with some coworkers designed a table 
classifying the EQAS in six categories according to their 
evaluation capabilities [7]. Category 1 schemes, based on 
commutable materials with target values assigned by ref-
erence methods, are the schemes that have full evaluation 
capabilities, and the authors conclude that, ideally, all 
EQAS should be category 1 schemes but are rare because 
of a number of constraints, including costs, technical dif-
ficulties and lack of awareness of the importance of these 
characteristics. Infusino et al. [8] proposed a further sub-
division of EQAS categories 1 and 2 in A and B: A, when 
using the higher order models for performance specifica-
tions identified by the EFLM Milan Strategic Conference 
[9], B if using lower levels.
Unfortunately, with the exception of a few examples 
[10–14], category 1 schemes remain scarce and so the real 
benefit of participation in EQAS remains modest. Other 
areas of laboratory medicine, where the experience of 
EQAS is more recent and/or deals with different type of 
measures, seem to benefit more from the participation in 
EQAS as reported for immunophenotyping [15] or micro-
biology [16]. In the Netherlands, the Calibration 2.000 
initiative is a nationwide program, established in 1998, 
which strived for either standardization or harmoniza-
tion of tests in domains beyond clinical chemistry such 
as hematology, endocrinology, coagulation, immunology, 
TDM, parasitology, etc. [11]. The output of its research was 
fed into the EQAS of the Dutch SKML and is reviewed in 
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this special issue [11]. Notwithstanding the achievements 
of Calibration 2.000 in the past 20 years, especially in the 
clinical chemistry domain, EQAS for the other domains 
are not yet at the category 1 level.
Open questions
Are EQAS really fit for purpose? The concept of traceability 
and trueness-based grading is typical for clinical chemistry 
and all other laboratory disciplines producing numerical 
results on a continuous scale. In the case that a reference 
measurement system is in place, category 1 EQAS should be 
implemented for an effective improvement of the analytical 
quality. On the contrary, participation in Miller’s category 
5 schemes only allows to make peer group comparisons [6]. 
As briefly indicated above, for real help in improving clini-
cal laboratories’ accuracy, verifying the calibration-related 
and/or specificity bias as well as imprecision of specific 
tests or analytical systems, the vast majority of the pres-
ently available EQAS are not fit for purpose. Exception to 
the rule is the EQAS and MUSE scoring system from the 
Dutch SKML [17], which allows to systematically distinguish 
bias and imprecision of tests. In other EQAS, the core of the 
problem is the control materials in the schemes that are not 
commutable or whose commutability is not verified or dem-
onstrated. The verification of commutability is extremely 
demanding both in terms of costs and time for realization 
[18–20] and thus not affordable for small schemes. More-
over, it is quite clear that manipulation of control materials 
to stabilize them (addition of exogenous substances, lyophi-
lization, etc.) and to obtain predefined measurand concen-
trations often brings along non-commutability [21, 22]. The 
production of suitable control materials requires research 
and investments and their distribution in frozen form is also 
expensive. Another important cost is the value assignment 
using reference methods. However, assigning target values 
with reference methods to non-commutable control materi-
als is not only useless but also dangerous because it may 
cause biases that do not exist but are only caused by non-
commutability, thus inducing undue corrective actions. All 
these reasons explain why the development of category 1 or 
2 EQAS is a significant challenge that therefore progresses 
slowly, notwithstanding all the literature evidence regard-
ing the absolute necessity of commutability of EQA mate-
rials in accuracy-based EQAS. Another relevant drawback 
that impairs the efficacy of some schemes is the use of inap-
propriate analytical quality specifications (APS) to evaluate 
the performances of the laboratories. Only when applying 
adequate APS, according to the model proposed by the first 
EFLM strategic conference [9], there is an effective relation-
ship between the test performances and the level of quality 
needed. EQAS should help laboratorians to make informed 
decisions about test accuracy by being enabled to verify the 
adequate implementation of the metrology concept through 
IVD manufacturers. Unfortunately, most EQAS are not 
equipped to do this and do not allow a proper verification 
of the correct implementation of the traceability concept, 
within allowable measurement uncertainties.
The situation is different when looking at EQAS 
devoted to assessing performance in pre- or postanalyti-
cal phases by circulating questionnaires or clinical cases 
or when distributing images or slides to assess the compe-
tence of the professionals [23–26]. In these cases, usually 
the improvement obtained is defined, even if it is difficult 
to quantify it and to demonstrate an objective efficacy.
Are all schemes equivalent and sufficiently harmo-
nized? Also this question has a negative reply. Apart 
from the different evaluation capabilities depending on 
the type of EQA materials used, there are several other 
reasons that create a very large heterogeneity in the EQA 
programs. Jones and coworkers [27] well identify these 
reasons that are summarized in six groups: (a) the nature 
of the EQAS material, including its commutability, which 
may affect the result interpretation; (b) the procedure 
used to assign the target value; (c) the data set to which 
performance specifications are applied (i.e. single result, 
series of data); (d) the analytical property being assessed 
(i.e. total error, bias, imprecision); (e) the rationale for the 
selection of the performance specification; and (f) type(s) 
of model used to set performance specifications. The 
problem of the evaluation criteria is very relevant, and 
their setting depends on the main scope of the program: if 
it has a regulatory impact, the criteria are looser because 
the scope is to identify the very poor performer; if it has an 
educational scope, the criteria are tighter because failing 
to meet them does not automatically imply sanctions but 
only a remedial action by the laboratory. This problem 
exists also outside clinical chemistry as indicated by 
Olson and coworkers for coagulation [28]. The situation 
may improve with the implementation on a larger scale of 
accreditation for EQA providers based on ISO 17043:2010 
[29]. Unfortunately, this ISO standard defines no require-
ments regarding commutability or performance specifica-
tions. In this situation of great heterogeneity of EQAS, just 
the participation in any type of EQAS is not sufficient in 
terms of verifying precision and metrological traceability 
of test results as well as compliance with ISO 15189:2012. 
Therefore, inspectors need to verify also this aspect [30].
Is the role of EQAS similar and necessary in all branches 
of laboratory medicine? The reply to this last question is 
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absolutely positive; no diagnostic discipline of the clinical 
laboratory can operate its test performance without EQAS 
from independent third parties. EQAS are essential tools for 
evaluating test result equivalence by comparing test results 
to value-assigned trueness verifiers in case of commutable 
EQAS (i.e. category 1 EQAS) or to peer group means in case of 
category 5 EQAS, and for detecting problematic, non-trace-
able tests, which can be traced back to specific IVD manu-
facturers. EQAS are very important tools for standardization 
and harmonization of laboratory practices. Paradoxically 
in some laboratory areas, apparently more complex than 
clinical chemistry, the problems of materials and accuracy 
evaluation seem less critical, e.g. for microbiology where 
microorganism identification is the gold standard and both 
traditional and molecular biology-based techniques can be 
successfully tested, with very good results [31]. Yet Schuurs 
et  al. [31] demonstrate that harmonization of PCR-based 
detection of intestinal pathogens is still in its infancy.
We conclude that harmonization of EQAS has still a 
long way to go, and much technical and organizational 
work has to be done, but important milestones indicating 
the way to follow have been defined [1, 7, 9, 11, 18]. Inten-
sive collaborations or alliances between country-specific 
EQA organizations under the umbrella of the European 
Organization for External Quality Assurance in Labora-
tory Medicine are urgently needed, as well as efforts to 
merge EQAS in countries where different schemes for the 
same measurands are in use. These efforts should allow to 
develop jointly affordable and sustainable category 1 EQA 
schemes by sharing expertise and enlarging market share 
in medical laboratories.
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